Stoke Therapeutics (NASDAQ:STOK) Insider Sells $209,539.24 in Stock

Key Points

• Insider sale: Director Barry Ticho sold 6,686 shares on March 18 for $209,539.24 (plus additional sales on March 17 and 19), cutting his holding by 14.08% to 40,798 shares, as disclosed in an SEC filing.
• The stock popped 7.0% to $33.19 on heavy volume (853,428), trading with a market cap of $1.96B, a P/E of 49.54, and a 52‑week range of $5.35–$40.22 (50‑ and 200‑day moving averages ~$32.61 and $29.90).
• Mixed fundamentals and outlook: the company missed quarterly expectations (EPS -$0.97 vs. -$0.75; revenue $1.4M vs. $5.3M), yet most analysts remain bullish with a consensus rating of "Moderate Buy" and an average target near $39.83.

Stoke Therapeutics, Inc. (NASDAQ:STOK - Get Free Report) insider Barry Ticho sold 6,686 shares of the company's stock in a transaction on Wednesday, March 18th. The shares were sold at an average price of $31.34, for a total transaction of $209,539.24. Following the completion of the transaction, the insider owned 40,798 shares of the company's stock, valued at $1,278,609.32. This represents a 14.08% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Barry Ticho also recently made the following trade(s):

• On Tuesday, March 17th, Barry Ticho sold 6,164 shares of Stoke Therapeutics stock. The stock was sold at an average price of $33.01, for a total value of $203,473.64.
• On Thursday, March 19th, Barry Ticho sold 1,461 shares of Stoke Therapeutics stock. The stock was sold at an average price of $29.99, for a total value of $43,815.39.

Stoke Therapeutics Trading Up 7.0%

Shares of Stoke Therapeutics stock traded up $2.17 on Thursday, hitting $33.19. The stock had a trading volume of 853,428 shares, compared to its average volume of 754,489. The stock has a market cap of $1.96 billion, a price-to-earnings ratio of 49.54 and a beta of 1.07. Stoke Therapeutics, Inc. has a 52-week low of $5.35 and a 52-week high of $40.22. The company's 50 day moving average price is $32.61 and its 200 day moving average price is $29.90.

Institutional Trading of Stoke Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the stock. AQR Capital Management LLC increased its holdings in shares of Stoke Therapeutics by 1.2% in the fourth quarter. AQR Capital Management LLC now owns 29,467 shares of the company's stock valued at $935,000 after purchasing an additional 354 shares during the period. Strs Ohio raised its stake in shares of Stoke Therapeutics by 9.4% during the fourth quarter. Strs Ohio now owns 7,000 shares of the company's stock worth $222,000 after purchasing an additional 600 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Stoke Therapeutics by 31.1% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,776 shares of the company's stock worth $88,000 after purchasing an additional 658 shares during the period. Generali Investments Management Co LLC grew its position in Stoke Therapeutics by 41.0% in the 4th quarter. Generali Investments Management Co LLC now owns 2,471 shares of the company's stock valued at $78,000 after buying an additional 718 shares during the last quarter. Finally, Kestra Advisory Services LLC purchased a new position in Stoke Therapeutics in the 4th quarter valued at $26,000.

Stoke Therapeutics News Summary

Here are the key news stories impacting Stoke Therapeutics this week:

• Positive Sentiment: Multiple analysts raised or reiterated bullish ratings and price targets this week (BTIG reaffirmed "buy" with a $39 target; Wedbush lifted its target to $38; Needham raised its target toward $40 and Chardan keeps a $35 target) — these actions increase buy-side interest and provide technical/supportive buying. Read More.
• Positive Sentiment: Pipeline story: coverage highlighting STK‑001’s potential to restore developmental deficits in Dravet syndrome (beyond seizure control) supports upside for long-term clinical value if trials continue to show benefit. Read More.
• Neutral Sentiment: Company granted inducement stock options to new hires — helps recruiting but adds potential future dilution; not an immediate earnings impact. Read More.
• Negative Sentiment: Quarterly results missed expectations: EPS of ($0.97) vs. consensus ($0.75) and revenue $1.4M vs. $5.3M expected — the earnings/revenue shortfall is the clearest near-term driver of prior downward pressure and investor concern about near-term commercialization/visibility. Read More.
• Negative Sentiment: Insider sale disclosed — Director Arthur A. Levin sold 605 shares (~$22k) in mid‑March; small in dollar terms but sometimes interpreted as a mild negative signal by short‑term traders. Read More.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on STOK shares. Wedbush increased their price objective on Stoke Therapeutics from $36.00 to $38.00 and gave the company an "outperform" rating in a report on Tuesday. BTIG Research reaffirmed a "buy" rating and issued a $39.00 target price on shares of Stoke Therapeutics in a report on Thursday. Wolfe Research started coverage on shares of Stoke Therapeutics in a research report on Monday, February 23rd. They issued an "outperform" rating and a $40.00 price target for the company. HC Wainwright increased their price target on shares of Stoke Therapeutics from $35.00 to $50.00 and gave the stock a "buy" rating in a research note on Monday, December 15th. Finally, UBS Group set a $50.00 price objective on shares of Stoke Therapeutics in a research report on Monday, December 15th. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat, Stoke Therapeutics presently has a consensus rating of "Moderate Buy" and an average target price of $39.83.

Stoke Therapeutics Company Profile

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company's lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.